方法：回顾性病例研究。纳入2016-03/2019-03期间医院收诊的确诊为缺血型BRVO继发ME患者71例71眼，按治疗方式不同将患者分为激光组33例33眼和联合组38例38眼，激光组患者接受577nm黄色阈下微脉冲激光光凝治疗，联合组患者接受康柏西普联合577nm黄色阈下微脉冲激光光凝治疗，比较两组患者治疗前，治疗后1、2、3、6、9、12mo患者患眼最佳矫正视力(BCVA)、黄斑中心视网膜厚度(CMT)以及总黄斑容积(TMV)变化情况，观察治疗疗效，并记录并发症发生情况。

结果：治疗后1、2、3、6、9、12mo，两组患者BCVA(LogMAR)、CMT、TMV明显低于治疗前(P<0.05)，且两组之间比较有差异(P<0.05)； 随访期间，联合组患者激光光凝1次者30眼，2次者7眼，3次者1眼，激光组患者激光光凝1次者16眼，2次者14眼，3次者3眼，两组比较有差异(Z=2.670，P<0.05)； 联合组患者在玻璃体腔注药后第1d有3眼出现5次角膜上皮剥落，对症治疗后症状得以消失。所有患者均未发生持续性眼压升高、视网膜剥离以及眼内炎症等严重并发症。

结论：康柏西普联合577nm黄色阈下微脉冲激光光凝治疗缺血型BRVO继发ME具有明显疗效，能够有效改善患者视力，促进ME吸收，安全可靠。

METHODS: Totally 71 patients(71 eyes)diagnosed as ME secondary to ischemic BRVO during the period from March 2016 to March 2019 were retrospectively included, and they were divided into laser group(n=33, 33 eyes)and combined group(n=38, 38 eyes)according to the different treatment methods. The patients in the laser group all received 577nm yellow subliminal micropulse laser photocoagulation, and the patients in the combined group all received Conbercept combined with 577nm yellow subliminal micropulse laser photocoagulation. The best corrected visual acuity(BCVA), central macular thickness(CMT)and total macular volume(TMV)were compared between the two groups before treatment and at 1, 2, 3, 6, 9 and 12mo after surgery, and the therapeutic efficacy was observed and the occurrence of complications were recorded.

RESULTS:There were statistically significant differences in the BCVA, CMT and TMV between the two groups before and after treatment(P<0.05), and the BCVA, CMT and TMV in the two groups at 1, 2, 3, 6, 9 and 12mo after treatment were significantly lower than those before treatment(P<0.05), and the differences between the two groups were statistically significant(P<0.05). During follow-up, there were 30 eyes with once laser photocoagulation, 7 eyes with twice and 1 eye with 3 times in combined group, and there were 16 eyes with once laser photocoagulation, 14 eyes with twice and 3 eyes with 3 times in laser group(Z=2.670, P<0.05). There were 3 eyes of corneal epithelial exfoliation on the 1d after vitreous injection in combined group, and the symptoms disappeared after symptomatic treatment. All patients did not have serious complications such as persistent intraocular pressure increase, retinal detachment and intraocular inflammation.

CONCLUSION: Conbercept combined with 577nm yellow subliminal micropulse laser photocoagulation has a significant efficacy in the treatment of ME secondary to ischemic BRVO, and it can effectively improve the visual acuity and promote the macular edema absorption, and it is safe and reliable.